Knowledge Library

Exceptional Performance OXGENE’s patented lentiviral plasmids deliver exceptional viral yields. Our pre-validated off the shelf packaging plasmids and custom-built genome plasmid are available royalty free at research, clinical GMP and commercial GMP grade. Antibiotic Free All plasmids are manufactured in an antibiotic free process for improved regulatory compliance. Regulatory Support Our regulatory package supports customers …Read More >

OXGENE’s proprietary cell and gene therapy manufacturing solutions help pioneering companies achieve high-titre, scalable and cost-effective viral vector production. Streamlined ordering and manufacturing processes accelerate turnaround times and expedited local and international delivery for both standard and custom plasmids at all grades. Planned local stocks of standard plasmids will further reduce delivery times. OXGENE’s plasmids …Read More >

Cancer immunotherapies aim to harness the immune system to fight tumours. Carisma Therapeutics is taking a novel approach to cancer immunotherapy by utilizing macrophages recruited to solid tumours as part of an immune response. Carisma aims to use chimeric antigen receptor (CAR) macrophages to prime the immune system to kill tumours. One of Carisma’s goals …Read More >

TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of nextgeneration immunotherapies for intractable haematologic malignancies and advanced solid tumours. TiCARos’ mission is to create medication based on science. TiCARos was founded by two leading T cell immunologists, who have built …Read More >